Fda expands authorized use of regen-cov™ (casirivimab and imdevimab)

Tarrytown, n.y., july 30, 2021 /prnewswire/ --  expanded authorization enables use of regen-cov for post-exposure prophylaxis in certain people exposed to a sars-cov-2 infected individual, or who are at high risk of exposure to an infected individual in an institutional setting supported by pivotal phase 3 data showing 81% reduced risk of symptomatic infections in close contacts of sars-cov-2 infected individuals only covid-19 antibody therapy currently available across the u.s. for both treatment and post-exposure prophylaxis; regen-cov retains potency against variants of concern use of regen-cov across the u.s. is rapidly increasing to address ongoing outbreaks regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) updated the emergency use authorization (eua) for the investigational covid-19 antibody cocktail regen-cov™ (casirivimab and imdevimab).
REGN Ratings Summary
REGN Quant Ranking